KEYLYNK-010: Phase III study of pembrolizumab (pembro) plus olaparib (OLA) vs enzalutamide (ENZA) or abiraterone (ABI) in ENZA- or ABI-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who had progression on chemotherapy (CTx)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz248.050
Abstract: Abstract Background In mCRPC pts unselected for homologous recombination deficiency (HRD), promising activity was seen with combination programmed death 1 inhibitor pembro and OLA in the phase 1b/2 KEYNOTE-365 study (NCT02861573), warranting further investigation in… read more here.
Keywords: abi enza; enza; pembro; genetics ... See more keywords
Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.264
Abstract: 264 Background: Abiraterone (Abi), enzalutamide (Enza) and docetaxel (Doc) are all valid first-line (1L) mCRPC treatment options. Evidence suggests a degree of cross-resistance between agents, which may impact the efficacy of subsequent lines of therapy.… read more here.
Keywords: abi; treatment; pts treated; doc ... See more keywords